Biochemical and stone-risk profiles with topiramate treatment.

  title={Biochemical and stone-risk profiles with topiramate treatment.},
  author={Brian J. Welch and Dion F Graybeal and Orson W Moe and Naim M. Maalouf and Khashayar Sakhaee},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  volume={48 4},
BACKGROUND Topiramate is a novel neuromodulatory agent commonly prescribed for the treatment of seizure disorders and for migraine headache prophylaxis. Calcium phosphate kidney stones have been observed with topiramate treatment, but a comprehensive elucidation of stone-risk profile was not reported previously. This study explores the relationship between topiramate treatment and propensity for kidney stone formation. METHODS Thirty-two topiramate-treated subjects and 50 healthy volunteers… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
33 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…